NCCN 2015 Updates

In CML, Assess Response to First-Line TKI at 3 Months

Wayne Kuznar

May 2015, Vol 6, No 4 - NCCN 2015 Updates

Hollywood, FL—Switching therapy in patients with chronic myelogenous leukemia (CML) should be considered in those who have a suboptimal response to a first-line tyrosine kinase inhibitor (TKI) at 3 months, said Jerald P. Radich, MD, Director of the Molecular Oncology Laboratory, Fred Hutchinson Cancer Research Center, Seattle, WA, and Vice Chair of the National Comprehensive Cancer Network (NCCN) guideline panel on CML. He discussed the management of patients with CML at the 2015 NCCN conference. [ Read More ]

Many Targeted Drugs in Development for Multiple Myeloma: Monoclonal Antibodies Close to Approval

Wayne Kuznar

May 2015, Vol 6, No 4 - NCCN 2015 Updates

Hollywood, FL—New targeted agents in multiple myeloma will turn it into a chronic illness, with sustained complete response possible in a significant fraction of patients, predicted Kenneth C. Anderson, MD, Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, at his presentation at the 2015 National Comprehensive Cancer Network (NCCN) conference. [ Read More ]

Promising Therapies in Multiple Drug Classes Being Explored for B-Cell Lymphomas

Wayne Kuznar

May 2015, Vol 6, No 4 - NCCN 2015 Updates

Hollywood, FL—Targeted therapy in B-cell lymphoma is rapidly expanding beyond anti-CD20 antibodies. Some of the emerging therapies are conjugated antibodies, treatments that target signaling pathways or apoptosis, immunomodulatory drugs (IMiDs), and immune checkpoint inhibitors, said Andrew D. Zelenetz, MD, PhD, Vice Chair, Medical Informatics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, at the 2015 National Comprehensive Cancer Network conference. [ Read More ]